Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Equities researchers at Wedbush lifted their FY2019 EPS estimates for shares of Eiger Biopharmaceuticals in a research note issued on Thursday, November 14th. Wedbush analyst L. Moussatos now forecasts that the biotechnology company will earn ($3.18) per share for the year, up from their prior forecast of ($3.22). Wedbush also issued estimates for Eiger Biopharmaceuticals’ Q4 2019 earnings at ($0.80) EPS, Q1 2020 earnings at ($0.80) EPS, Q2 2020 earnings at ($0.82) EPS, Q3 2020 earnings at ($0.83) EPS, Q4 2020 earnings at ($0.82) EPS, FY2020 earnings at ($3.27) EPS, FY2021 earnings at ($3.21) EPS and FY2022 earnings at ($2.52) EPS.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.01).
A number of other analysts have also recently issued reports on EIGR. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $28.00 target price on shares of Eiger Biopharmaceuticals in a research report on Monday, November 11th. BidaskClub raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 30th. ValuEngine cut Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Finally, Zacks Investment Research cut Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $28.67.
Shares of NASDAQ EIGR opened at $11.65 on Monday. The stock has a market cap of $281.20 million, a PE ratio of -3.05 and a beta of 1.02. The company has a quick ratio of 6.83, a current ratio of 6.83 and a debt-to-equity ratio of 0.44. Eiger Biopharmaceuticals has a 52-week low of $8.40 and a 52-week high of $15.33. The business has a 50-day moving average price of $10.68 and a 200 day moving average price of $10.77.
A number of institutional investors have recently bought and sold shares of the business. Tocqueville Asset Management L.P. lifted its position in Eiger Biopharmaceuticals by 5.6% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 36,175 shares of the biotechnology company’s stock worth $371,000 after acquiring an additional 1,925 shares during the period. Bank of Montreal Can acquired a new stake in Eiger Biopharmaceuticals during the 2nd quarter worth approximately $28,000. Lindbrook Capital LLC acquired a new stake in Eiger Biopharmaceuticals during the 3rd quarter worth approximately $36,000. Tower Research Capital LLC TRC lifted its position in Eiger Biopharmaceuticals by 1,719.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,895 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 4,626 shares during the period. Finally, P.A.W. Capital Corp lifted its position in Eiger Biopharmaceuticals by 5.3% during the 2nd quarter. P.A.W. Capital Corp now owns 200,000 shares of the biotechnology company’s stock worth $2,120,000 after acquiring an additional 10,000 shares during the period. 84.36% of the stock is owned by institutional investors.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
Recommended Story: Hang Seng Index (HSI)
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.